Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV

BACKGROUND: Antiangiogenic agents have been shown to stimulate the immune system and cause synergistic effects with chemotherapy. Effects might be even stronger after immune-checkpoint-inhibitor (ICI) therapy. The purpose of this analysis was to evaluate the efficacy of ramucirumab plus docetaxel (R...

Descripción completa

Detalles Bibliográficos
Autores principales: Brueckl, Wolfgang M, Reck, Martin, Rittmeyer, Achim, Kollmeier, Jens, Wesseler, Claas, Wiest, Gunther H, Christopoulos, Petros, Tufman, Amanda, Hoffknecht, Petra, Ulm, Bernhard, Reich, Fabian, Ficker, Joachim H, Laack, Eckart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440727/
https://www.ncbi.nlm.nih.gov/pubmed/32884390
http://dx.doi.org/10.1177/1179554920951358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440727/
https://www.ncbi.nlm.nih.gov/pubmed/32884390
http://dx.doi.org/10.1177/1179554920951358

Ejemplares similares